Literature DB >> 31811986

Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature.

Chiara Zanetta1, Micaela Robotti1, Agostino Nozzolillo1, Francesca Sangalli1, Giuseppe Liberatore2, Eduardo Nobile-Orazio2, Massimo Filippi3, Lucia Moiola1.   

Abstract

Entities:  

Keywords:  Anti-CD20; Late onset absolute neutropenia; Monoclonal antibody treatment; Multiple sclerosis; Ocrelizumab; Treatment naïve

Mesh：

Substances：

Year:  2019        PMID： 31811986     DOI： 10.1016/j.jns.2019.116603

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN： 0022-510X            Impact factor:   3.181


× No keyword cloud information.
  8 in total

1.  Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient.

Authors:  Mariano Marrodan; Julia Laviano; Sofía Oneto; Fabricio M Reino; Ricardo Delorme; Florencia Fornillo; José Férnandez; Jorge Correale
Journal:  Neurol Sci       Date:  2021-06-01       Impact factor: 3.307

2.  Late-onset neutropenia (LON) recur in a MS patient after the second cycle of ocrelizumab: a case report.

Authors:  Giorgia T Maniscalco; Lia Allegorico; Maria Elena Di Battista; Mario Annunziata; Simona Salvatore; Valentino Manzo
Journal:  Neurol Sci       Date:  2021-06-25       Impact factor: 3.307

3.  Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis.

Authors:  Tereza Gabelić; Barbara Barun; Ivan Adamec; Magdalena Krbot Skorić; Mario Habek
Journal:  Hum Vaccin Immunother       Date:  2021-10-20       Impact factor: 4.526

4.  Severe Delayed-Onset Neutropenia Induced by Ocrelizumab.

Authors:  Jonatha Baird-Gunning; James Yun; William Stevenson; Karl Ng
Journal:  Neurohospitalist       Date:  2020-07-09

Review 5.  [Ocrelizumab for treatment of multiple sclerosis].

Authors:  Jonas Graf; Philipp Albrecht; Norbert Goebels; Orhan Aktas; Hans-Peter Hartung
Journal:  Nervenarzt       Date:  2020-06-10       Impact factor: 1.214

Review 6.  Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.

Authors:  Georges Jalkh; Rachelle Abi Nahed; Gabrielle Macaron; Mary Rensel
Journal:  Vaccines (Basel)       Date:  2020-12-26

7.  Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study.

Authors:  Nabil Seery; Sifat Sharmin; Vivien Li; Ai-Lan Nguyen; Claire Meaton; Roberts Atvars; Nicola Taylor; Kelsey Tunnell; John Carey; Mark P Marriott; Katherine A Buzzard; Izanne Roos; Chris Dwyer; Josephine Baker; Lisa Taylor; Kymble Spriggs; Trevor J Kilpatrick; Tomas Kalincik; Mastura Monif
Journal:  CNS Drugs       Date:  2021-04-13       Impact factor: 5.749

8.  Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: A case report.

Authors:  Robin Rauniyar; Rahul Rauniyar; Ankita Agrawal; Shikha Yadav; Sreekant Avula
Journal:  Clin Case Rep       Date:  2022-01-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.